1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Mixed Data For Bluebird's LentiGlobin, But Conditional Approval On The Cards

 
• By Lucie Ellis-Taitt

Over the last week bluebird bio has reported first interim Phase III data from the Northstar-2 trial of blood disease drug LentiGlobin and announced a public offering of $350m of common stock.

Blood sample
Bluebird looks towards 2017 EU conditional approval for LentiGlobin as beta-thalassemia gene therapy • Source: Shutterstock

Gene therapy specialist bluebird bio Inc. has reported early Phase III data for LentiGlobin (lentiviral beta-globin gene transfer) in patients with transfusion-dependent beta-thalassemia (TDT) that have split analysts' opinions.

Despite mixed figures from the first three patients treated in the Northstar-2 trial, the results have demonstrated that bluebird's improved manufacturing process can

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.